Orphazyme A/S (Nasdaq Copenhagen: ORPHA.CO) is a biopharmaceutical company focusing on the development of innovative new therapies for the treatment of a protein misfolding disorders. The company’s proprietary approach utilizes the lysosome-protective and stabilizing effect of Heat Shock Proteins as a platform for the development of novel therapies. The lead compound, Arimoclomol, is in clinical development in Niemann-Pick Type C, ALS and sIBM.

Sten Verland, PhD MSc

General Partner

Mobile: +45 24 22 19 69